Small Fiber Neuropathy and Isotretinoin: Reported Cases
Yes, cases of small fiber neuropathy have been reported with isotretinoin administration, though the evidence is limited and conflicting. The available research suggests predominantly sensory nerve involvement rather than isolated small fiber neuropathy, and the clinical significance remains uncertain.
Evidence from Research Studies
The literature contains several reports documenting peripheral neuropathy associated with isotretinoin therapy:
Mid-term therapy effects: A prospective study of 28 patients receiving isotretinoin 1 mg/kg/day for 6 months found that 72% (20/28) displayed abnormal electroneurographic findings, with significant decreases in sensory conduction velocities across multiple nerves 1. The changes suggested predominantly sensory demyelinating neuropathy rather than pure small fiber involvement.
Mixed findings on duration: A 2007 study documented abnormal neurophysiological findings pointing toward "typical distal, length-dependent and predominantly sensory polyneuropathy" in patients on isotretinoin 2. However, this contrasts with another prospective study of 18 patients that found no clinical or subclinical neuropathy after 1-3 months of isotretinoin treatment at 1 mg/kg/day 3.
Case report evidence: One case report documented both sacroiliitis and sensorimotor demyelinating polyneuropathy during isotretinoin therapy, with mild improvement noted 2 years after drug withdrawal 4.
FDA Drug Label Information
The FDA label for isotretinoin does not specifically list small fiber neuropathy as a recognized adverse effect 5. The neurological warnings focus primarily on:
- Pseudotumor cerebri (benign intracranial hypertension)
- Hearing impairment
- Vision problems
- Depression and psychiatric effects
Clinical Interpretation
Important caveats:
- The reported neuropathies appear to involve both small and large fibers, not isolated small fiber neuropathy
- The time course varies considerably (3-6 months in most studies)
- One well-designed study found no neuropathy with short-term use 3
- The changes may be subclinical (detected only on electroneuromyography) without clinical symptoms
- Reversibility remains unclear, though one case showed mild improvement after discontinuation 4
Practical Recommendations
For patients reporting sensory symptoms during isotretinoin therapy:
- Perform detailed neurological examination focusing on distal sensory function
- Consider electroneuromyography if paresthesias, numbness, or sensory loss develop 2
- Evaluate for both small and large fiber involvement
- Document baseline symptoms before initiating therapy in high-risk patients
Risk assessment: The absolute risk appears low based on available data, but clinicians should maintain awareness that peripheral nerve dysfunction—potentially including small fiber components—can occur during isotretinoin therapy. The predominantly sensory pattern and distal distribution are characteristic features when neuropathy does develop.
The evidence does not support routine screening for small fiber neuropathy in asymptomatic patients on isotretinoin, but symptomatic patients warrant thorough neurological evaluation.